GHZ339 / Novartis - LARVOL DELTA

GHZ339: Primary data readout from P2 PLATFORM-AD trial (NCT06947993) for moderate to severe atopic dermatitis in 2028 (Novartis) - Q1 2026 Results

P2 data • Atopic Dermatitis

GHZ339: Regulatory submission in US for atopic dermatitis in 2029 or later (Novartis) - Q1 2026 Results

FDA filing • Atopic Dermatitis

CADPT17A12201: Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=104 | Recruiting | Sponsor: Novartis Pharma AG

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=224 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology